Hapten

Hapten designates small molecules that cannot independently trigger immune responses but become immunogenic when coupled to larger carrier proteins, forming complete antigens recognised by immune systems. These low-molecular-weight compounds include drugs, environmental chemicals, or industrial compounds that covalently modify proteins creating novel epitopes, potentially triggering allergic reactions or hypersensitivity responses.

The pharmaceutical industry addresses hapten-related concerns throughout drug development, particularly for small molecules and conjugated therapeutics. Drug-induced immune responses often involve hapten mechanisms where reactive metabolites or parent drugs covalently bind proteins creating immunogenic complexes. Safety assessment evaluates potential for drugs or metabolites forming haptens through covalent protein binding studies, predicting immunogenicity risk. Antibody-drug conjugates intentionally employ hapten principles coupling cytotoxic drugs to antibodies. Structure-activity relationships guide design minimising hapten formation potential through structural modifications. As understanding grows regarding hapten chemistry, development strategies increasingly incorporate hapten considerations from discovery through clinical use.